Peptides for recovery and anabolism: mechanisms, benefits, risks and smart combinations
Peptides for recovery and anabolism — how the GHRH/ghrelin agonists and the tripeptide glutathione act; when and how they are combined for recovery and body composition.
Basic concepts: peptides, tripeptides, the GH–IGF-1 axis
A peptide is a chain of a few amino acids, joined by peptide bonds. The length and the sequence determine receptor selectivity, pharmacokinetics and biological action.
A tripeptide contains three amino acids. A classic example: glutathione (GSH) — glutamate–cysteine–glycine — with an active thiol group (–SH) for antioxidant protection and redox balance.
The GH–IGF-1 axis: Some molecules (GHRH analogues and ghrelin agonists) stimulate pulsatile endogenous GH secretion, increase IGF-1 and support remodelling, sleep and body composition. It differs from exogenous GH (somatropin), which is non-pulsatile.
Recovery vs. anabolism
- Recovery: normalisation of markers after loading, reduction of inflammation and oxidative stress, improved sleep and quality of connective tissue.
- Anabolism: stimulation of protein/myofibril synthesis, maintenance of lean mass and better insulin sensitivity.
The processes support each other: without quality recovery there is no sustainable anabolic response.
Peptide profiles (in the catalogue and as references)
CJC-1295 without DAC (GHRH analogue)
How it acts: a short-acting GHRH analogue that enhances the physiological pulsatile GH secretions. The “without DAC” version aims at a shorter, physiological exposure.
Benefits: support of NREM sleep, regeneration and collagen remodelling; frequently combined with a GHS-R agonist (see Ipamorelin).
Tesamorelin
How it acts: a modified GHRH analogue that increases GH/IGF-1 and shows targeted metabolic effects on visceral fat.
Benefits: metabolic focus — body composition, lipid profile, insulin sensitivity in specific populations.
Ipamorelin (GHS-R agonist)
How it acts: a selective agonist of the ghrelin receptor (GHS-R), it causes endogenous, pulsatile GH secretion with minimal effect on ACTH/cortisol compared with GHRP-2/-6.
Benefits: improvement of sleep/recovery quality; supports maintenance of lean mass and tissue remodelling (indirectly via IGF-1).
Sermorelin (GHRH-(1–29))
How it acts: a classic GHRH analogue (fragment 1–29) with a short half-life, it mimics the natural dynamics of the GH pulse.
Benefits: a “mild” and physiological profile; preferred when minimal intervention is sought.
Somatropin (exogenous GH) — reference point
Recombinant human growth hormone (rhGH). Included as a point of comparison: it administers exogenous GH, is non-pulsatile and has a separate risk/regulatory profile. It is not offered as a research product in our catalogue.
Glutathione — a tripeptide for redox protection
How it acts: the main cellular redox buffer. In its reduced form (GSH) it neutralises peroxides via glutathione peroxidase, is oxidised to GSSG and is recycled to GSH by glutathione reductase (with NADPH). A high GSH:GSSG ratio indicates a protective intracellular environment.
Benefits: moderates oxidative stress after loading, supports hepatic conjugation (phase II), works in synergy with GH-axis regulators in regeneration protocols.
What the studies show – in brief
- GHRH analogues (Sermorelin, CJC-1295 without DAC, Tesamorelin): increase GH in pulses; IGF-1 within reference ranges; often better sleep and body composition.
- GHS-R agonists (Ipamorelin): ↑GH with a low likelihood of ↑ACTH/cortisol; good tolerance; synergy with GHRH analogues.
- Antioxidants (Glutathione): lower markers of lipid peroxidation and higher-quality regeneration under high stress.
- Somatropin: a strong effect, but non-pulsatile and with a separate risk profile; a point of comparison, not a research peptide.
Smart combinations (in a research context)
- GHRH + GHS-R synergy: CJC-1295 without DAC/Sermorelin + Ipamorelin → a stronger but physiological GH peak.
- Metabolic focus: Tesamorelin ± Ipamorelin → visceral fat and body composition.
- Redox “shield”: Glutathione as a background under high training volumes or intense stimulation of the GH axis.
- Connective tissue: GHRH analogue + redox support, together with adequate protein intake.
The combinations require monitoring of IGF-1, glucose, lipids and subjective markers of sleep/recovery.
When they are not used / caution
- Active neoplasms/unclarified tumours — agents that increase IGF-1 or proliferation are avoided.
- Uncontrolled hyperglycaemia/severe insulin resistance — GH-axis regulators affect glucose homeostasis.
- Severe heart disease/oedema — possible fluid retention.
- Pregnancy/breastfeeding; minors — no.
- Anti-doping regime — many molecules are on the WADA List.
- Known allergies/hypersensitivities to excipients/solvents.
Practical notes for protocols
- Pulsatility vs. exposure: Sermorelin/CJC without DAC → short “pulses”; tesamorelin → targeted metabolic profile.
- Synchronisation with sleep: GH peak at night → evening timing and sleep hygiene are often tried.
- Nutrition/protein: the anabolic signal needs a substrate (amino acids; for connective tissue — collagen).
- Redox balance: higher anabolism → more ROS; GSH and NADPH support are logical.
Selection matrix
| Goal/focus | Suitable peptides | Comment |
|---|---|---|
| Recovery + sleep | Sermorelin or CJC-1295 without DAC + Ipamorelin | Pulsatility and GHRH/GHS-R synergy |
| Metabolic focus | Tesamorelin ± Ipamorelin | Visceral fat, monitoring of IGF-1 |
| Antioxidant “shield” | Glutathione | Reduction of oxidative stress |
FAQ
Do “peptides” replace training and sleep?
No. They are regulators. Without a training stimulus, nutrition and sleep, the results are limited.
Is exogenous GH (somatropin) “better”?
A different approach with a separate risk profile and medical indications. In a research context, endogenous, pulsatile stimulation via GHRH/GHS-R is preferred.
Does Glutathione make sense with excellent habits?
Under high training volumes and signs of oxidative stress — often yes; form/dose depending on the goal.
Sources
- Peptology – Category “Peptides for muscle growth and recovery”.
- Raun K. et al. “Ipamorelin, the first selective GH secretagogue.” (PubMed).
- Teichman S.L. et al. “CJC-1295, a long-acting GHRH analog.” (PubMed).
- Falutz J. et al. “Tesamorelin and visceral adiposity — randomized trials.” (PMID 20647200).
- Veldhuis J.D., Bowers C.Y. “Human GH pulsatility & GHRH/Ghrelin physiology.” (Review).
- Redox biology of glutathione in muscle recovery (Review, PMC).
- WADA Prohibited List — GH & secretagogues.